Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
Atomo Diagnostics Ltd.Telephone
61.02.9099.4750
Address
Level 1 3-5 George Street Leichardt, New South Wales (NSW) 2040
Description
Atomo Diagnostics Ltd. engages in manufacture, research, development, and design of in-vitro medical devices for blood-based rapid diagnostic testing (RDT) for professional use and self-testing. It offers its products through the AtomoRapid range of RDT platforms. The company was founded by John Kelly in 2010 and is headquartered in Leichhardt, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.02 - 0.06
Trade Value (12mth)
AU$4,903.00
1 week
0%
1 month
4.76%
YTD
-8.33%
1 year
0%
All time high
0.63
EPS 3 yr Growth
0.90%
EBITDA Margin
-134.60%
Operating Cashflow
-$5m
Free Cash Flow Return
-37.60%
ROIC
-54.90%
Interest Coverage
-577.90
Quick Ratio
4.80
Shares on Issue (Fully Dilluted)
639m
HALO Sector
Healthcare
Next Company Report Date
28-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
29 October 24 |
Quarterly Activities Report and Appendix 4C
×
Quarterly Activities Report and Appendix 4C |
24 October 24 |
Atomo Investor Webinar Presentation
×
Atomo Investor Webinar Presentation |
23 October 24 |
Atomo Secures $2.44m Grant to Develop Syphilis Test
×
Atomo Secures $2.44m Grant to Develop Syphilis Test |
15 October 24 |
2024 Notice of Annual General Meeting
×
2024 Notice of Annual General Meeting |
29 August 24 |
2024 Appendix 4E and Annual Report
×
2024 Appendix 4E and Annual Report |
29 August 24 |
FY24 Results Presentation
×
FY24 Results Presentation |
29 August 24 |
2024 Appendix 4G and Corporate Governance Statement
×
2024 Appendix 4G and Corporate Governance Statement |
29 August 24 |
Atomo Investor Webinar Presentation
×
Atomo Investor Webinar Presentation |
25 July 24 |
Quarterly Activities Report and Appendix 4C
×
Quarterly Activities Report and Appendix 4C |
22 July 24 |
Atomo Investor Webinar Presentation
×
Atomo Investor Webinar Presentation |
09 July 24 |
Notification of cessation of securities - AT1
×
Notification of cessation of securities - AT1 |
09 July 24 |
Change of Director's Interest Notice - John Kelly
×
Change of Director's Interest Notice - John Kelly |
12 June 24 |
Government funded procurement of Atomo HIV tests commencing
×
Government funded procurement of Atomo HIV tests commencing |
11 June 24 |
Change of Company Secretary
×
Change of Company Secretary |
16 May 24 |
Significant funding to HIV Self-Testing in Federal Budget
×
Significant funding to HIV Self-Testing in Federal Budget |
30 April 24 |
Notification of cessation of securities - AT1
×
Notification of cessation of securities - AT1 |
29 April 24 |
Quarterly Activities Report and Appendix 4C
×
Quarterly Activities Report and Appendix 4C |
24 April 24 |
Atomo Investor Webinar Presentation
×
Atomo Investor Webinar Presentation |
15 April 24 |
AT1 secures significant order for HIV self-tests
×
AT1 secures significant order for HIV self-tests |
06 March 24 |
AT1 secures significant order for HIV self tests for LMIC
×
AT1 secures significant order for HIV self tests for LMIC |
04 March 24 |
Change of Company Secretary
×
Change of Company Secretary |
26 February 24 |
Appendix 4D and Half Year Report ended 31 Dec 2023
×
Appendix 4D and Half Year Report ended 31 Dec 2023 |
26 February 24 |
H1 FY24 Results Presentation
×
H1 FY24 Results Presentation |
21 February 24 |
Investor Webinar Presentation
×
Investor Webinar Presentation |
29 January 24 |
Appendix 4C - 31 December 2023
×
Appendix 4C - 31 December 2023 |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.